Skip to main content
. 2021 Aug 28;10(17):3864. doi: 10.3390/jcm10173864

Figure 9.

Figure 9

Associations of dynamic changes in serum biomarkers levels with changes in physiologic and functional measures in the progressors subgroup of patients with IPF over the first and second year of anti-fibrotic treatment. Notes: Panels showing a correlation between (A) a change in FVC% pred. and a change in SP-D serum levels in the first year of anti-fibrotic therapy; (B) a change in 6MWT distance and a change in CCL18 serum levels in the first year of anti-fibrotic therapy; (C) a change in FVC% pred. and a change in KL-6 serum levels in the second year of anti-fibrotic therapy; Abbreviations: FVC—forced vital capacity, 6MWT—six-minute walk test, SP-D—surfactant protein D, KL-6—Krebs von den Lungen-6, CCL18—chemokine (C-C motif) ligand 18, IPF—idiopathic pulmonary fibrosis.